Adalvo has successfully defended the European patent protecting our innovative Lisdexamfetamine oral solution.
Following oral proceedings before the Opposition Division of the European Patent Office on 17 February 2026, the patent — opposed by an anonymous third party — was upheld as granted. The decision remains open to appeal within standard timeframes.
This protection covers our ready-to-use liquid formulation developed with Labomed. It provides a value-added alternative to existing capsule and chewable presentations and strengthens our IP position in Europe through to 2039, with additional coverage in the United States.
Lisdexamfetamine is indicated for ADHD in patients aged six and above. Our oral solution addresses a clear clinical need — particularly for patients who require flexible, precise dosing or who have difficulty swallowing capsules.
This outcome highlights the strength of our innovation strategy and reinforces our commitment to delivering differentiated, patient-focused medicines that make a real difference.